ACE and ACE2 in inflammation: A tale of two enzymes

Inflammation and Allergy - Drug Targets

Volumn 13, Issue 4, 2014, Pages 224-234

  Gaddam, Ravinder Reddy ^a   Chambers, Stephen ^a   Bhatia, Madhav ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Angiotensin II; Angiotensin (1 7); Angiotensin converting enzyme; Angiotensin converting enzyme 2; AT1 receptor; Inflammation; Mas receptors; Renin angiotensin system

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; DIPEPTIDYL CARBOXYPEPTIDASE; HYDROGEN SULFIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRBESARTAN; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE; MYELOPEROXIDASE; ANGIOTENSIN I; ANGIOTENSIN I (1-7); ANGIOTENSIN II; PEPTIDE FRAGMENT;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; AMINO ACID SEQUENCE; ARTICLE; CARDIOVASCULAR INFLAMMATION; DOWN REGULATION; GENE DELETION; HEPATITIS; IMMUNE RESPONSE; INFLAMMATION; LIVER FIBROSIS; LUNG EDEMA; NEPHRITIS; OXIDATIVE STRESS; PANCREATITIS; PNEUMONIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RHEUMATOID ARTHRITIS; SEPSIS; ANIMAL; HUMAN; METABOLISM; PHYSIOLOGY;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; HUMANS; INFLAMMATION; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM;

EID: 84930882620     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871528113666140713164506     Document Type: Article

References (145)

1. Ferrario C.M. The renin-angiotensin system: importance in physiology and pathology. J. Cardiovasc. Pharmacol., 1990, 15(1), S1-S5.
2. Reid I.A.; Morris B.J.; Ganong W.F. The renin-angiotensin system. Annu. Rev. Physiol., 1978, 40(1), 377-410.
3. Ondetti M.; Cushman D. Enzymes of the renin-angiotensin system and their inhibitors. Annu. Rev. Biochem., 1982, 51(1), 283-308.
4. Dandona P.; Dhindsa S.; Ghanim H.; Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J. Hum. Hypertens., 2007, 21(1), 20-27.
5. Guang C.; Phillips R.D.; Jiang B.; Milani F. Three key proteasesangiotensin-I-converting enzyme (ACE), ACE2 and renin--within and beyond the renin-angiotensin system. Arch. Cardiovasc. Dis., 2012, 105(6-7), 373-385.
6. Piqueras L.; Nabah Y.N.A.; Escudero P.; Blanes J.I.; Jose P.J.; Morcillo E.J.; Sanz M.J. Contributions of ACE and mast cell chymase to endogenous angiotensin II generation and leucocyte recruitment in vivo. Cardiovasc. Res., 2011, 92(1), 48-56.
7. le Tran Y.; Forster C. Angiotensin-(1-7) and the rat aorta: modulation by the endothelium. J. Cardiovasc. Pharmacol., 1997, 30(5), 676-682.
8. Ferreira A.J.; Castro C.H.; Guatimosim S.; Almeida P.W.; Gomes E.R.; Dias-Peixoto M.F.; Alves M.N.; Fagundes-Moura C.R.; Rentzsch B.; Gava E. Attenuation of isoproterenol-induced cardiac fibrosis in transgenic rats harboring an angiotensin-(1-7)-producing fusion protein in the heart. Ther. Adv. Cardiovasc. Dis., 2010, 4(2), 83-96.
9. Komatsu H.; Yamada S.; Iwano H.; Okada M.; Onozuka H.; Mikami T.; Yokoyama S.; Inoue M.; Kaga S.; Nishida M. Angiotensin II receptor blocker, valsartan, increases myocardial blood volume and regresses hypertrophy in hypertensive patients. Circ. J., 2009, 73(11), 2098-2103.
10. Kuba K.; Imai Y.; Penninger J.M. Angiotensin-converting enzyme 2 in lung diseases. Curr. Opin. Pharmacol., 2006, 6(3), 271-276.
11. Santos R.A.; Ferreira A.J.; Simões e Silva A.C. Recent advances in the angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis. Exp. Physiol., 2008, 93(5), 519-527.
12. Ferrario C.M.; Chappell M.C. Novel angiotensin peptides. Cell. Mol. Life Sci., 2004, 61(21), 2720-2727.
13. Donoghue M.; Hsieh F.; Baronas E.; Godbout K.; Gosselin M.; Stagliano N.; Donovan M.; Woolf B.; Robison K.; Jeyaseelan R. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res., 2000, 87(5), e1-e9.
14. Santos R.A.; e Silva A.C.S.; Maric C.; Silva D.M.; Machado R.P.; de Buhr I.; Heringer-Walther S.; Pinheiro S.V.B.; Lopes M.T.; Bader M. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natil. Acad. Sci., 2003, 100(14), 8258-8263.
15. Santos R.A.; Campagnole-Santos M.J.; Andrade S.l.P. Angiotensin-(1-7): an update. Regul. Pept., 2000, 91(1), 45-62.
16. Vickers C.; Hales P.; Kaushik V.; Dick L.; Gavin J.; Tang J.; Godbout K.; Parsons T.; Baronas E.; Hsieh F. Hydrolysis of biological peptides by human angiotensin-converting enzymerelated carboxypeptidase. J. Biol. Chem., 2002, 277(17), 14838-14843.
17. Ferrario C.M.; Chappell M.C.; Tallant E.A.; Brosnihan K.B.; Diz D.I. Counterregulatory actions of angiotensin-(1-7). Hypertension, 1997, 30(3), 535-541.
18. Burrell L.M.; Johnston C.I.; Tikellis C.; Cooper M.E. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol. Metab., 2004, 15(4), 166-169.
19. Herath C.B.; Warner F.J.; Lubel J.S.; Dean R.G.; Jia Z.; Lew R.A.; Smith A.I.; Burrell L.M.; Angus P.W. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. J. Hepatol., 2007, 47(3), 387-395.
20. Ferrario C.M. ACE2: more of Ang-(1-7) or less Ang II? Curr. Opin. Nephrol. Hypertens., 2011, 20(1), 1-6.
21. Giani J.F.; Burghi V.; Veiras L.C.; Tomat A.; Muñoz M.C.; Cao G.; Turyn D.; Toblli J.E.; Dominici F.P. Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. Am. J. Physiol. Renal Physiol., 2012, 302(12), F1606-F1615.
22. Iyer S.N.; Chappell M.C.; Averill D.B.; Diz D.I.; Ferrario C.M. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension, 1998, 31(2), 699-705.
23. Klein N.; Gembardt F.; Supé S.; Kaestle S.M.; Nickles H.; Erfinanda L.; Lei X.; Yin J.; Wang L.; Mertens M. Angiotensin-(1-7) Protects From Experimental Acute Lung Injury. Crit. Care Med., 2013, 41(11), e334-e343.
24. Gembardt F.; Sterner-Kock A.; Imboden H.; Spalteholz M.; Reibitz F.; Schultheiss H.P.; Siems W.E.; Walther T. Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides, 2005, 26(7), 1270-1277.
25. Iyer S.N.; Ferrario C.M.; Chappell M.C. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the reninangiotensin system. Hypertension, 1998, 31(1), 356-361.
26. Fournie-Zaluski M.C.; Fassot C.; Valentin B.; Djordjijevic D.; Reaux-Le Goazigo A.; Corvol P.; Roques B.P.; Llorens-Cortes C. Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of saltdependent hypertension. Proc. Natl. Acad. Sci. U. S. A., 2004, 101(20), 7775-7780.
27. Danilczyk U.; Eriksson U.; Oudit G.Y.; Penninger J.M. Physiological roles of angiotensin-converting enzyme 2. Cell. Mol. Life Sci., 2004, 61(21), 2714-2719.
28. Simões e Silva A.; Silveira K.; Ferreira A.; Teixeira M. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br. J. Pharmacol., 2013, 169(3), 477-492.
29. Ohishi M.; Yamamoto K.; Rakugi H. Angiotensin (1-7) and other angiotensin peptides. Curr. Pharm. Des., 2013, 19(17), 3060-3064.
30. Li W.; Moore M.J.; Vasilieva N.; Sui J.; Wong S.K.; Berne M.A.; Somasundaran M.; Sullivan J.L.; Luzuriaga K.; Greenough T.C. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 2003, 426(6965), 450-454.
31. Nagata S.; Kato J.; Sasaki K.; Minamino N.; Eto T.; Kitamura K. Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem. Biophys. Res. Commun., 2006, 350(4), 1026-1031.
32. Trask A.J.; Jessup J.A.; Chappell M.C.; Ferrario C.M. Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am. J. Physiol. Heart Circ. Physiol., 2008, 158.
33. Jessup J.A.; Trask A.J.; Chappell M.C.; Nagata S.; Kato J.; Kitamura K.; Ferrario C.M. Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats. Am. J. Physiol. Heart Circ. Physiol., 2008, 294(6), H2614.
34. Nagata S.; Kato J.; Kuwasako K.; Asami M.; Kitamura K. Plasma and tissue concentrations of proangiotensin-12 in rats treated with inhibitors of the renin-angiotensin system. Hypertens. Res., 2012, 35(2), 234-238.
35. Hubert C.; Houot A.-M.; Corvol P.; Soubrier F. Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene. J. Biol. Chem., 1991, 266(23), 15377-15383.
36. Rawlings N.D.; Barrett A.J. Evolutionary families of peptidases. Biochem. J, 1993, 290(1), 205-218.
37. Rivière G.; Michaud A.; Breton C.; VanCamp G.; Laborie C.; Enache M.; Lesage J.; Deloof S.; Corvol P.; Vieau D. Angiotensinconverting enzyme 2 (ACE2) and ACE activities display tissuespecific sensitivity to undernutrition-programmed hypertension in the adult rat. Hypertension, 2005, 46(5), 1169-1174.
38. Tipnis S.R.; Hooper N.M.; Hyde R.; Karran E.; Christie G.; Turner A.J. A human homolog of angiotensin-converting enzyme cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem., 2000, 275(43), 33238-33243.
39. Riordan J.F. Angiotensin-I-converting enzyme and its relatives. Genome Biol., 2003, 4(8), 225.
40. Douglas G.C.; O’Bryan M.K.; Hedger M.P.; Lee D.K.; Yarski M.A.; Smith A.I.; Lew R.A. The novel angiotensin-converting enzyme (ACE) homolog, ACE2, is selectively expressed by adult Leydig cells of the testis. Endocrinology, 2004, 145(10), 4703-4711.
41. Xia H.; Suda S.; Bindom S.; Feng Y.; Gurley S.B.; Seth D.; Navar L.G.; Lazartigues E. ACE2-mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function. PLoS One, 2011, 6(7), e22682.
42. Kuba K.; Imai Y.; Penninger J.M. Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases. Circ. J., 2013, 77(2), 301-308.
43. Lambert D.W.; Clarke N.E.; Turner A.J. Not just angiotensinases: new roles for the angiotensin-converting enzymes. Cell. Mol. Life Sci., 2010, 67(1), 89-98.
44. Huentelman M.J.; Grobe J.L.; Vazquez J.; Stewart J.M.; Mecca A.P.; Katovich M.J.; Ferrario C.M.; Raizada M.K. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp. Physiol., 2005, 90(5), 783-790.
45. Zhang H.; Wada J.; Hida K.; Tsuchiyama Y.; Hiragushi K.; Shikata K.; Wang H.; Lin S.; Kanwar Y.S.; Makino H. Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. J. Biol. Chem., 2001, 276(20), 17132-17139.
46. Skeggs L.T.; Dorer F.E.; Kahn J.R.; Lentz K.E.; Levine M. The biochemistry of the renin-angiotensin system and its role in hypertension. Am. J. Med., 1976, 60(6), 737-748.
47. Towler P.; Staker B.; Prasad S.G.; Menon S.; Tang J.; Parsons T.; Ryan D.; Fisher M.; Williams D.; Dales N.A. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J. Biol. Chem., 2004, 279(17), 17996-18007.
48. Rella M.; Elliot J.L.; Revett T.J.; Lanfear J.; Phelan A.; Jackson R.M.; Turner A.J.; Hooper N.M. Identification and characterisation of the angiotensin converting enzyme-3 (ACE3) gene: a novel mammalian homologue of ACE. BMC Genomics, 2007, 8(1), 194.
49. Inoue N.; Kasahara T.; Ikawa M.; Okabe M. Identification and disruption of sperm-specific angiotensin converting enzyme-3 (ACE3) in mouse. PLoS One, 2010, 5(4), e10301.
50. Nicholls M.; Richards A.; Agarwal M. The importance of the renin-angiotensin system in cardiovascular disease. J. Hum. Hypertens., 1998, 12(5), 295-299.
51. Parajuli N.; Ramprasath T.; Patel V.B.; Wang W.; Putko B.; Mori J.; Oudit G.Y. Targeting angiotensin-converting enzyme 2 as a new therapeutic target for cardiovascular diseases. Can. J. Physiol. Pharmacol., 2014, 92(7), 558-565.
52. Dagenais N.J.; Jamali F. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy, 2005, 25(9), 1213-1229.
53. Gonzalez-Villalobos R.A.; Shen X.Z.; Bernstein E.A.; Janjulia T.; Taylor B.; Giani J.F.; Blackwell W.-L.B.; Shah K.H.; Shi P.D.; Fuchs S. Rediscovering ACE: novel insights into the many roles of the angiotensin-converting enzyme. J. Mol. Med., 2013, 91(10), 1143-1154.
54. Tham D.M.; Martin-McNulty B.; Wang Y.; Wilson D.W.; Vergona R.; Sullivan M.E.; Dole W.; Rutledge J.C. Angiotensin II is associated with activation of NF-kB-mediated genes and downregulation of PPARs. Physiol Genomics, 2002, 11(1), 21-30.
55. Nakamura S.; Nakamura I.; Ma L.; Vaughan D.E.; Fogo A.B. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo1. Kidney Int., 2000, 58(1), 251-259.
56. Boehm M.; Nabel E.G. Angiotensin-converting enzyme 2-a new cardiac regulator. N. Engl. J. Med., 2002, 347(22), 1795-1797.
57. Passos-Silva D.G.; Verano-Braga T.; Santos R.A. Angiotensin-(1-7): beyond the cardio-renal actions. Clin. Sci., 2013, 124(7), 443-456.
58. Gironacci M.M.; Coba M.P.; Peña C. Angiotensin-(1-7) binds at the type 1 angiotensin II receptors in rat renal cortex. Regul. Pept., 1999, 84(1), 51-54.
59. Souza L.L.; Costa-Neto C.M. Angiotensin-(1-7) decreases LPSinduced inflammatory response in macrophages. J. Cell. Physiol., 2012, 227(5), 2117-2122.
60. Rubenfeld G.D.; Caldwell E.; Peabody E.; Weaver J.; Martin D.P.; Neff M.; Stern E.J.; Hudson L.D. Incidence and outcomes of acute lung injury. N. Engl. J. Med., 2005, 353(16), 1685-1693.
61. Imai Y.; Kuba K.; Rao S.; Huan Y.; Guo F.; Guan B.; Yang P.; Sarao R.; Wada T.; Leong-Poi H. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature, 2005, 436(7047), 112-116.
62. Salgado D.R.; Rocco J.R.; Silva E.; Vincent J.L. Modulation of the renin-angiotensin-aldosterone system in sepsis: a new therapeutic approach? Expert Opin. Ther. Targets, 2010, 14(1), 11-20.
63. Imai Y.; Kuba K.; Ohto-Nakanishi T.; Penninger J.M. Angiotensinconverting enzyme 2 (ACE2) in disease pathogenesis. Circ. J., 2010, 74(3), 405-410.
64. Hagiwara S.; Iwasaka H.; Hidaka S.; Hasegawa A.; Koga H.; Noguchi T. Antagonist of the type-1 ANG II receptor prevents against LPS-induced septic shock in rats. Intensive Care Med., 2009, 35(8), 1471-1478.
65. Shen L.; Mo H.; Cai L.; Kong T.; Zheng W.; Ye J.; Qi J.; Xiao Z. Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. Shock, 2009, 31(5), 500-506.
66. Richardson M.A.; Gupta A.; O’Brien L.A.; Berg D.T.; Gerlitz B.; Syed S.; Sharma G.R.; Cramer M.S.; Heuer J.G.; Galbreath E.J. Treatment of sepsis-induced acquired protein C deficiency reverses Angiotensin-converting enzyme-2 inhibition and decreases pulmonary inflammatory response. J. Pharmacol. Exp. Ther., 2008, 325(1), 17-26.
67. Jin H.Y.; Song B.; Oudit G.Y.; Davidge S.T.; Yu H.M.; Jiang Y.Y.; Gao P.J.; Zhu D.L.; Ning G.; Kassiri Z. ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production. PLoS One, 2012, 7(6), e38502.
68. Kranzhofer R.; Browatzki M.; Schmidt J.; Kubler W. Angiotensin II activates the proinflammatory transcription factor nuclear factorkappaB in human monocytes. Biochem. Biophys. Res. Commun., 1999, 257(3), 826-828.
69. Celec P. Nuclear factor kappa B-molecular biomedicine: the next generation. Biomed. Pharmacother., 2004, 58(6), 365-371.
70. Ware L.B.; Matthay M.A. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med., 2001, 163(6), 1376-1383.
71. Bader M.; Ganten D. Update on tissue renin-angiotensin systems. J. Mol. Med., 2008, 86(6), 615-621.
72. Montezano A.C.; Cat A.N.D.; Rios F.J.; Touyz R.M. Angiotensin II and Vascular Injury. Curr. Hypertens. Rep., 2014, 16(6), 1-11.
73. Yamamoto Y.; Gaynor R.B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J. Clin. Invest., 2001, 107(2), 135-142.
74. Rocha R.; Funder J.W. The pathophysiology of aldosterone in the cardiovascular system. Ann. N. Y. Acad. Sci., 2002, 970(1), 89-100.
75. Liu C.C.; Karimi G.K.; Weisbrod R.M.; Hansen T.; Ravaie R.; Nunez A.; Liu Y.B.; Fry N.; Garcia A.; Hamilton E.J. Oxidative inhibition of the vascular Na+-K+ pump via NADPH oxidasedependent β1-subunit glutathionylation: implications for angiotensin II-induced vascular dysfunction. Free Radic. Biol. Med., 2013, 65(563-572.
76. Tesanovic S.; Vinh A.; Gaspari T.A.; Casley D.; Widdop R.E. Vasoprotective and Atheroprotective Effects of Angiotensin (1-7) in Apolipoprotein E-Deficient Mice. Arterioscler. Thromb. Vasc. Biol., 2010, 30(8), 1606-1613.
77. Verma S. Angiotensin Converting Enzyme-2 (ACE2) confers endothelial protection and attenuates atherosclerosis. Am. J. Physiol. Heart Circ. Physiol., 2008, 295(4), H1377- H1384.
78. Dong B.; Zhang C.; Feng J.B.; Zhao Y.X.; Li S.Y.; Yang Y.P.; Dong Q.L.; Deng B.P.; Zhu L.; Yu Q.T. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2008, 28(7), 1270-1276.
79. Thomas M.C.; Pickering R.J.; Tsorotes D.; Koitka A.; Sheehy K.; Bernardi S.; Toffoli B.; Nguyen-Huu T.-P.; Head G.A.; Fu Y. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ. Res., 2010, 107(7), 888-897.
80. Oudit G.Y.; Kassiri Z.; Patel M.P.; Chappell M.; Butany J.; Backx P.H.; Tsushima R.G.; Scholey J.W.; Khokha R.; Penninger J.M. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc. Res., 2007, 75(1), 29-39.
81. Ohshima K.; Mogi M.; Nakaoka H.; Iwanami J.; Min L.J.; Kanno H.; Tsukuda K.; Chisaka T.; Bai H.Y.; Wang X.L.; Ogimoto A.; Higaki J.; Horiuchi M. Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade. Hypertension, 2014, 63(3), e53-e59.
82. Kassiri Z.; Zhong J.; Guo D.; Basu R.; Wang X.; Liu P.P.; Scholey J.W.; Penninger J.M.; Oudit G.Y. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ. Heart Fail., 2009, 2(5), 446-455.
83. Hassona M.D.; Elnakish M.T.; Abouelnaga Z.A.; Alhaj M.; Wani A.A.; Hassanain H. The effect of selective antihypertensive drugs on the vascular remodeling-associated hypertension: Insights from a profilin1 transgenic mouse model. J. Cardiovasc. Pharmacol., 2011, 57(5), 550-558.
84. Crackower M.A.; Sarao R.; Oudit G.Y.; Yagil C.; Kozieradzki I.; Scanga S.E.; Oliveira-dos-Santos A.J.; da Costa J.; Zhang L.; Pei Y. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature, 2002, 417(6891), 822-828.
85. Bodiga S.; Zhong J.C.; Wang W.; Basu R.; Lo J.; Liu G.C.; Guo D.; Holland S.M.; Scholey J.W.; Penninger J.M. Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47phox NADPH oxidase subunit. Cardiovasc. Res., 2011, 91(1), 151-161.
86. Ferreira A.J.; Santos R.A.; Almeida A.P. Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension, 2001, 38(3), 665-668.
87. Santos R.A.; Ferreira A.J.; Nadu A.P.; Braga A.N.; de Almeida A.P.; Campagnole-Santos M.J.; Baltatu O.; Iliescu R.; Reudelhuber T.L.; Bader M. Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats. Physiological Genomics, 2004, 17(3), 292-299.
88. Hanafy S.; Tavasoli M.; Jamali F. Inflammation alters angiotensin converting enzymes (ACE and ACE-2) balance in rat heart. Inflammation, 2011, 34(6), 609-613.
89. Purushothaman K.R.; Purushothaman M.; Muntner P.; Lento P.A.; O’Connor W.N.; Sharma S.K.; Fuster V.; Moreno P.R. Inflammation, neovascularization and intra-plaque hemorrhage are associated with increased reparative collagen content: implication for plaque progression in diabetic atherosclerosis. Vasc. Med., 2011, 16(2), 103-108.
90. Zhong J.C.; Ye J.Y.; Jin H.Y.; Yu X.; Yu H.M.; Zhu D.l.; Gao P.J.; Huang D.Y.; Shuster M.; Loibner H. Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regul. Pept., 2011, 166(1), 90-97.
91. Cheng J.F.; Ni G.H.; Chen M.F.; Li Y.J.; Wang Y.J.; Wang C.L.; Yuan Q.; Shi R.Z.; Hu C.P.; Yang T.L. Involvement of profilin-1 in angiotensin II-induced vascular smooth muscle cell proliferation. Vascul. Pharmacol., 2011, 55(1), 34-41.
92. Liu G.C.; Oudit G.Y.; Fang F.; Zhou J.; Scholey J.W. Angiotensin-(1-7)-induced activation of ERK1/2 is cAMP/protein kinase Adependent in glomerular mesangial cells. Am. J. Physiol. Renal Physiol., 2012, 302(6), F784-F790.
93. Ruiz-Ortega M.; Esteban V.; Ruperez M.; Sanchez-Lopez E.; Rodríguez-Vita J.; Carvajal G.; Egido J. Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr. Opin. Nephrol. Hypertens., 2006, 15(2), 159-166.
94. Ruiz-Ortega M.; Lorenzo O.; Rupérez M.; Suzuki Y.; Egido J. Angiotensin II activates nuclear transcription factor-κB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout mice. Nephrol. Dial. Transplant., 2001, 16(1), 27-33.
95. Satoh M.; Kashihara N.; Yamasaki Y.; Maruyama K.; Okamoto K.; Maeshima Y.; Sugiyama H.; Sugaya T.; Murakami K.; Makino H. Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice. J. Am. Soc. Nephrol., 2001, 12(2), 317-325.
96. Casas J.P.; Chua W.; Loukogeorgakis S.; Vallance P.; Smeeth L.; Hingorani A.D.; MacAllister R.J. Effect of inhibitors of the reninangiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. The Lancet, 2005, 366(9502), 2026-2033.
97. MacKinnon M.; Shurraw S.; Akbari A.; Knoll G.A.; Jaffey J.; Clark H.D. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am. J. Kidney Dis., 2006, 48(1), 8-20.
98. Wolf G. Link between angiotensin II and TGF-beta in the kidney. Miner. Electrolyte Metab., 1998, 24(2-3), 174-180.
99. Yoo K.H.; Thornhill B.A.; Wolstenholme J.T.; Chevalier R.L. Tissue-specific regulation of growth factors and clusterin by angiotensin II. Am. J. Hypertens., 1998, 11(6 Pt 1), 715-722.
100. Diamond J.R.; Kreisberg R.; Evans R.; Nguyen T.A.; Ricardo S.D. Regulation of proximal tubular osteopontin in experimental hydronephrosis in the rat. Kidney Int., 1998, 54(5), 1501-1509.
101. Guo G.; Morrissey J.; McCracken R.; Tolley T.; Klahr S. Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am. J. of Physiol.-Renal Physiol., 1999, 277(5), F766-F772.
102. Wolak T.; Kim H.; Ren Y.; Kim J.; Vaziri N.D.; Nicholas S.B. Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int., 2009, 76(1), 32-43.
103. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int., 2006, 70(11), 1914-1919.
104. Gounder V.K.; Arumugam S.; Arozal W.; Thandavarayan R.A.; Pitchaimani V.; Harima M.; Suzuki K.; Nomoto M.; Watanabe K. Olmesartan protects against oxidative stress possibly through the Nrf2 signaling pathway and inhibits inflammation in daunorubicininduced nephrotoxicity in rats. Int. Immunopharmacol., 2014, 18(2), 282-289.
105. Sparks M.A.; Crowley S.D.; Gurley S.B.; Mirotsou M.; Coffman T.M. Classical Renin-Angiotensin system in kidney physiology. Compr Physiol, 2014, 4(3), 1201-1228.
106. Batlle D.; Wysocki J.; Soler M.J.; Ranganath K. Angiotensinconverting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy. Kidney Int., 2012, 81(6), 520-528.
107. Wong D.W.; Oudit G.Y.; Reich H.; Kassiri Z.; Zhou J.; Liu Q.C.; Backx P.H.; Penninger J.M.; Herzenberg A.M.; Scholey J.W. Loss of Angiotensin-Converting Enzyme-2 (Ace2) Accelerates Diabetic Kidney Injury. Am. J. Pathol., 2007, 171(2), 438-451.
108. Zhang J.; Noble N.A.; Border W.A.; Huang Y. Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. Am. J. of Physiol. Renal Physiol., 2010, 298(3), F579-F588.
109. Mori J.; Patel V.B.; Ramprasath T.; Alrob O.A.; DesAulniers J.; Scholey J.W.; Lopaschuk G.D.; Oudit G.Y. Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. Am. J. of Physiol. Renal Physiol., 2014, 306(8), F812-F821.
110. Esteban V.; Heringer-Walther S.; Sterner-Kock A.; de Bruin R.; van den Engel S.; Wang Y.; Mezzano S.; Egido J.; Schultheiss H.P.; Ruiz-Ortega M. Angiotensin-(1-7) and the g protein-coupled receptor MAS are key players in renal inflammation. PLoS One, 2009, 4(4), e5406.
111. Zimmerman D.; Burns K.D. Angiotensin-(1-7) in kidney disease: a review of the controversies. Clin. Sci., 2012, 123(6), 333-346.
112. Schuppan D.; Porov Y. Hepatic fibrosis: from bench to bedside. J. Gastroenterol. Hepatol., 2002, 17(3), S300-S305.
113. Yang L.; Bataller R.N.; Dulyx J.; Coffman T.M.; Ginès P.; Rippe R.A.; Brenner D.A. Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J. Hepatol., 2005, 43(2), 317-323.
114. Bataller R.; Schwabe R.F.; Choi Y.H.; Yang L.; Paik Y.H.; Lindquist J.; Qian T.; Schoonhoven R.; Hagedorn C.H.; Lemasters J.J. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J. Clin. Invest., 2003, 112(9), 1383-1394.
115. Bataller R.; Gäbele E.; Schoonhoven R.; Morris T.; Lehnert M.; Yang L.; Brenner D.A.; Rippe R.A. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am. J. Physiol. Gastroint. Liver Physiol., 2003, 285(3), G642-G651.
116. Paizis G.; Gilbert R.E.; Cooper M.E.; Murthi P.; Schembri J.M.; Wu L.L.; Rumble J.R.; Kelly D.J.; Tikellis C.; Cox A. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J. Hepatol., 2001, 35(3), 376-385.
117. Tuncer I.; Ozbek H.; Ugras S.; Bayram I. Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat: the effect of AT1-R blocker on the hepatic fibrosis. Exp. Toxicol. Pathol., 2003, 55(2), 159-166.
118. Wei H.S.; Lu H.M.; Li D.G.; Zhan Y.T.; Wang Z.R.; Huang X.; Cheng J.L.; Xu Q.F. The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis: effects of RAS inhibitors on hepatic fibrosis induced by CCl~ 4. World J. Gastroenterol., 2000, 6(6), 824-828.
119. Jonsson J.R.; Clouston A.D.; Ando Y.; Kelemen L.I.; Horn M.J.; Adamson M.D.; Purdie D.M.; Powell E.E. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology, 2001, 121(1), 148-155.
120. Ohishi T.; Saito H.; Tsusaka K.; Toda K.; Inagaki H.; Hamada Y.; Kumagai N.; Atsukawa K.; Ishii H. Anti-fibrogenic effect of an angiotensin converting enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats. Hepatol. Res., 2001, 21(2), 147-158.
121. Yoshiji H.; Kuriyama S.; Yoshii J.; Ikenaka Y.; Noguchi R.; Nakatani T.; Tsujinoue H.; Fukui H. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology, 2001, 34(4), 745-750.
122. Zhang W.; Miao J.; Li P.; Wang Y.; Zhang Y. Up-regulation of components of the renin-angiotensin system in liver fibrosis in the rat induced by CCL(4). Res. Vet. Sci., 2013, 95(1), 54-58.
123. Österreicher C.H.; Taura K.; De Minicis S.; Seki E.; PenzÖsterreicher M.; Kodama Y.; Kluwe J.; Schuster M.; Oudit G.Y.; Penninger J.M. Angiotensin-converting-enzyme 2 inhibits liver fibrosis in mice. Hepatology, 2009, 50(3), 929-938.
124. Santos S.H.S.; Andrade J.M.O.; Fernandes L.R.; Sinisterra R.D.; Sousa F.B.; Feltenberger J.D.; Alvarez-Leite J.I.; Santos R.A.S. Oral Angiotensin-(1-7) prevented obesity and hepatic inflammation by inhibition of resistin/TLR4/MAPK/NF-κB in rats fed with highfat diet. Peptides, 2013, 46, 47-52.
125. Niu M.J.; Yang J.K.; Lin S.S.; Ji X.J.; Guo L. M. Loss of angiotensin-converting enzyme 2 leads to impaired glucose homeostasis in mice. Endocrine, 2008, 34(1-3), 56-61.
126. Bindom S.M.; Lazartigues E. The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol. Cell. Endocrinol., 2009, 302(2), 193-202.
127. Bindom S.M.; Hans C.P.; Xia H.; Boulares A.H.; Lazartigues E. Angiotensin I-Converting Enzyme Type 2 (ACE2) Gene Therapy Improves Glycemic Control in Diabetic Mice. Diabetes, 2010, 59(10), 2540-2548.
128. Leung P.; Carlsson P.O. Tissue renin-angiotensin system: its expression, localization, regulation and potential role in the pancreas. J. Mol. Endocrinol., 2001, 26(3), 155-164.
129. Ip S.P.; Kwan P.C.; Williams C.H.; Pang S.; Hooper N.M.; Leung P.S. Changes of angiotensin-converting enzyme activity in the pancreas of chronic hypoxia and acute pancreatitis. Int. J. Biochem. Cell Biol., 2003, 35(6), 944-954.
130. Tsang S.W.; Ip S.P.; Leung P.S. Prophylactic and therapeutic treatments with AT1 and AT2 receptor antagonists and their effects on changes in the severity of pancreatitis. Int. J. Biochem. Cell Biol., 2004, 36(2), 330-339.
131. Teplitsky V.; Shoenfeld Y.; Tanay A. The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans. Lupus, 2006, 15(6), 319-325.
132. Ip S.P.; Tsang S.W.; Wong T.P.; Che C.T.; Leung P.S. Saralasin, a nonspecific angiotensin II receptor antagonist, attenuates oxidative stress and tissue injury in cerulein-induced acute pancreatitis. Pancreas, 2003, 26(3), 224-229.
133. Fink A.S.; Wang Y.; Mendez T.; Worrell R.T.; Eaton D.; Nguyen T.D.; Lee S.P. Angiotensin II evokes calcium-mediated signaling events in isolated dog pancreatic epithelial cells. Pancreas, 2002, 25(3), 290-295.
134. Liu R.; Qi H.; Wang J.; Wang Y.; Cui L.; Wen Y.; Yin C. Ulinastatin activates the renin-angiotensin system to ameliorate the pathophysiology of severe acute pancreatitis. J. Gastroenterol. Hepatol., 2014, 29(6), 1328-1337.
135. Wang Y.; Wang J.; Liu R.; Qi H.; Wen Y.; Sun F.; Yin C. Severe acute pancreatitis is associated with upregulation of the ACE2- angiotensin-(1-7)-Mas axis and promotes increased circulating angiotensin-(1-7). Pancreatology, 2012, 12(5), 451-457.
136. Wållberg-Jonsson S.; Johansson H.; Ohman M.; Rantapää-Dahlqvist S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J. Rheumatol., 1999, 26(12), 2562-2571.
137. da Silveira K.D.; Coelho F.M.; Vieira A.T.; Sachs D.; Barroso L.C.; Costa V.V.; Bretas T.L.B.; Bader M.; de Sousa L.P.; da Silva T.A. Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J. Immunol., 2010, 185(9), 5569-5576.
138. Kaplan M.J. Cardiovascular disease in rheumatoid arthritis. Curr. Opin. Rheumatol., 2006, 18(3), 289-297.
139. Bhatia M.; Sidhapuriwala J.N.; Sparatore A.; Moore P.K. Treatment with H2S-releasing diclofenac protects mice against acute pancreatitis-associated lung injury. Shock, 2008, 29(1), 84-88.
140. Bhatia M.; Wong F.L.; Fu D.; Lau H.Y.; Moochhala S.M.; Moore P.K. Role of hydrogen sulfide in acute pancreatitis and associated lung injury. The FASEB journal, 2005, 19(6), 623-625.
141. Ang A.D.; Rivers-Auty J.; Hegde A.; Ishii I.; Bhatia M. The effect of CSE gene deletion in caerulein-induced acute pancreatitis in the mouse. American Journal of Physiology-Gastrointestinal and Liver Physiology, 2013, 305(10), G712-G721.
142. Zhang H.; Zhi L.; Moore P.K.; Bhatia M. Role of hydrogen sulfide in cecal ligation and puncture-induced sepsis in the mouse. Am. J. Physiol. Lung Cell Mol. Physiol., 2006, 290(6), L1193-L1201.
143. Zhang J.; Sio S.W.S.; Moochhala S.; Bhatia M. Role of Hydrogen Sulfide in Severe Burn Injury-Induced Inflammation in Mice. Mol. Med., 2010, 16(9-10), 417-424.
144. Bhatia M.; Sidhapuriwala J.; Moochhala S.M.; Moore P.K. Hydrogen sulphide is a mediator of carrageenan-induced hindpaw oedema in the rat. Br. J. Pharmacol., 2005, 145(2), 141-144.
145. Laggner H.; Hermann M.; Esterbauer H.; Muellner M.K.; Exner M.; Gmeiner B.M.; Kapiotis S. The novel gaseous vasorelaxant hydrogen sulfide inhibits angiotensin-converting enzyme activity of endothelial cells. J. Hypertens., 2007, 25(10), 2100-2104.